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Virtual screeningAbstract Thermolysin is a bacterial proteolytic enzyme, considered by many authors as a pharma-
cological and biological model of other mammalian enzymes, with similar structural characteristics,
such as angiotensin converting enzyme and neutral endopeptidase. Inhibitors of these enzymes are
considered therapeutic targets for common diseases, such as hypertension and heart failure. In this
report, a mathematical model of Multiple Linear Regression, for ordinary least squares, and genetic
algorithm, for selection of variables, are developed and implemented in QSARINS software, with
appropriate parameters for its fitting. The model is extensively validated according to OECD stan-
dards, so that its robustness, stability, low correlation of descriptors and good predictive power are
proven. In addition, it is found that the model fit is not the product of a random correlation. Two
possible outliers are identified in the model application domain but, in a molecular docking study,
they show good activity, so we decide to keep both in our database. Finally, 141 and 69 compounds
(2.5 6 pKi < 3.5 and pKiP 3.5, respectively) are identified as potential Thermolysin inhibitors,22085,
co study
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based on QSARINS and docking. Arabian Jconcluding that the proposed computational tools are an efficient method for the identification of
new drugs that could inhibit this enzyme.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
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Thermolysin (EC 3.4.24.27) was one of the first metalloproteases
whose structure was obtained crystallographically; therefore, it has
been studied extensively as an archetype of zinc metalloendopeptidases
(Marchand-Geneste et al., 2002). It is a heat-stable extracellular
endopeptidase with molecular weight of 34,600 Da. Thermolysin
(TLN) is classified within the family M4 metalloendopeptidases
(http://merops.sanger.ac.uk/) (Adekoya and Sylte, 2009). This prote-
olytic enzyme contains a zinc ion, essential for catalytic activity, and
four calcium ions required for thermal stability (Waller and
Marshall, 1993). This enzyme is specific for peptide bonds containing
the amino group of hydrophobic amino acid residues, such as L-
leucine, L-isoleucine, and L-phenylalanine (Morihara and Tswzu,
1970). The mechanism of action of Thermolysin proposed by Brian
Matthews was emerged from an extended series of structural studies.
In native Thermolysin the zinc ion has approximate tetrahedral coor-
dination, with three ligands provided by the protein (His 142 and His
146 in the motif HEXXH, and Glu 166 in the motif EXXXD) and the
fourth provided by a water molecule (Matthews, 1988).
The zinc-metalloproteinases secreted by the gram-positive ther-
mophilic bacterium Bacillus thermoproteolyticus is the prototype of
the TLN family and has served as a model system to study the inhibi-
tion mechanism of other metalloproteinases. Crystallographic data for
TLN and various TLN-inhibitor complexes have been used in efforts
to model the active site of other TLN-like enzyme (Bohacek et al.,
1996; Tiraboschi, 1999). These enzymes play a key role in the biosyn-
thesis and metabolism of different bioactive peptides, so that its inhi-
bitors have considerable potential as therapeutic agents (Holland
et al., 1994). In addition, Thermolysin presents close structural and
functional similarities with several mammalian enzymes that are
involved in the control of different physiological functions, like nepri-
lysin (NEP) and angiotensin-converting enzyme (ACE), both involved
in the control of blood pressure.
Angiotensin I-converting enzyme (ACE, EC 3.4.15.1) belongs to
the M2 family of Zinc-binding metalloproteinases, within the MA clan.
ACE plays an important role in blood pressure homeostasis by cleav-
ing the C-terminal dipeptide from angiotensin I to produce the potent
vasopressor peptide angiotensin II (Rang, 2003) and inactivates the
vasodilatory peptide bradykinin by the sequential removal of two C-
terminal dipeptides (Yang et al., 1970). This enzyme contains two
Zinc-coordinating catalytic domains (N and C domains) each bearing
the HEXXH motif where the two histidines form two of the three
amino acid ligands, while a glutamate 24 residues downstream forming
the third ligand (Williams et al., 1994). The role of a Zn ion in ACE
catalysis was thought to be analogous to that in TLN (Soubrier,
1988). As a consequence of these structural and functional similarities
and the role of ACE in the metabolism of those two vaso-active pep-
tides, the active site of TLN has been used as a model to develop highly
potent and specific ACE inhibitors.
Neprilysin (neutral endopeptidase; NEP, EC 3.4.24.11) is an inte-
gral plasma membrane ectopeptidase of the M13 family of Zinc metal-
loproteinases. Like TLN and ACE, NEP possesses the HEXXH motif
as well as a consensus sequence EXIXD in which the glutamate (Glu)
serves as the third Zn ligand (Roques, 1993; Roques et al., 1993;
Williams et al., 1994). NEP is involved in the metabolism of a number
of regulatory peptides of the mammalian cardiovascular, inflamma-
tory, nervous and immune systems (Bland, 2008). Therefore, NEP is
potential therapeutic targets in cardiovascular and inflammatoryCarmenate, Y. et al., An approach to id
ournal of Chemistry (2016), http://dx.ddisorders. Before the crystal structure of NEP-inhibitor complex was
solved, the structure and function similarities between NEP and
TLN served as the basis of NEP inhibitor design by using TLN as a
test model. Selective inhibitors, such as phosphoramidon have con-
tributed to understanding NEP enzyme function (Holland et al.,
1994). This enzyme catalyzes the vasodilatory peptide degradation:
natriuretic peptides, substance P and enkephalins (Turner et al., 2001).
According to this, TLN was previously used to construct the NEP
and ACE models, which guided in the design of NEP/ACE inhibitors.
The dual inhibition of neprilysin and the angiotensin receptor may rep-
resent an attractive therapeutic approach for a wide range of cardio-
vascular diseases, including hypertension, diabetes and heart or
kidney failure, in which vasoconstriction, volume overload and neuro-
hormonal activation play a role in the pathophysiology (Manzur et al.,
2013). The structural and functional similarities between TLN, NEP
and ACE indicate that Thermolysin inhibitors may also inhibit ACE
and NEP and be putative antihypertensives (Khan et al., 2009). Dual
NEP/ACE inhibitors repress simultaneously two key enzymes that
participate in cardiovascular function regulation (Ruilope et al.,
2012). This type of inhibitors exerted typical actions of ACE inhibitors
and/or NEP inhibitors, such as dose-dependent inhibition of angioten-
sin I–induced hypertension, protection of atrial natriuretic factor, and
enhancement of diuresis, natriuresis, and cGMP urinary excretion
(Laurent et al., 2000).
According to the World Health Organization, cardiovascular dis-
ease accounts globally for approximately 17 million deaths a year
and, of these, complications of hypertension account for 9.4 million
deaths worldwide every year. Hypertension is responsible for at least
45% of deaths due to heart disease and 51% of deaths due to stroke.
In 2014, the worldwide prevalence of hypertension in adults over
18 years was about 22% (World Health Organization, 2016). Given
the large number of persons affected by these diseases, efforts are con-
tinuously made in the field of drug research, with the aim of finding
new agents to optimize their management (Unger et al., 2011). Still,
the prognosis for these patients remains grim, and many treatment
options are unsatisfactory. In addition, we can say that the treatment
and the response of patients with decompensated heart failure have not
changed substantially in recent decades. As a result of the foregoing,
there is a critical need to find new drugs to improve clinical outcomes
(Aronson and Krum, 2012; Manzur et al., 2013).
The QSAR studies are useful tools for screening chemicals, espe-
cially in early stages of the drug discovery process, which have pro-
vided no experimental data. If these are properly developed and
rigorously validated (Gramatica et al., 2013b), they become outstand-
ing tools to evaluate only those that are most promising. In the last two
decades, QSAR models have been successfully used to search new
molecular entities (Bhadoriya et al., 2014; Nazarshodeh et al., 2015;
Sahu et al., 2014), correlating significant structural properties with
the biological activity of a compound. In this sense, our research group
have obtained several remarkable results in the identification/selection
of new molecular entities with potential action against different targets
(Brito-Sa´nchez et al., 2013; Castillo-Garit et al., 2012, 2015a,b, 2009;
Le-Thi-Thu et al., 2016). The main objective of the present study
was to obtain a statistically significant model to predict the Ther-
molysin inhibition and to identify new hits, which could be potential
antihypertensive agents. We used the QSARINS software to develop
a Multiple Linear Regression (MLR) model to identify the potentially
new inhibitors; it was validated according to OECD standards (Worth
et al., 2007).entify new antihypertensive agents using Thermolysin as model: In silico study
oi.org/10.1016/j.arabjc.2016.10.003
Figure 1 Diagram of variables filtering process.
Figure 2 Model performance according to number of variables.
An approach to identify new antihypertensive agents 32. Materials and methods
2.1. Thermolysin inhibitors database
The database was collected from reports of the international
literature (see Fig. S-1 and Table S-1 of supplementary mate-
rial). These compounds are reversible competitive inhibitorsPlease cite this article in press as: Can˜izares-Carmenate, Y. et al., An approach to id
based on QSARINS and docking. Arabian Journal of Chemistry (2016), http://dx.dof Thermolysin enzyme and have reported enzyme inhibition
constants (Ki) covering a range of 6.8  108 to 430 nM.
Due to the inhibition wide range of the compounds, we
decided to work with pKi (log Ki), which varied from
2.63 to 7.16. The database of 176 experimental compounds
was divided into training (133 compounds) and prediction
(43 compounds).entify new antihypertensive agents using Thermolysin as model: In silico study
oi.org/10.1016/j.arabjc.2016.10.003
Figure 3 Scatter plot of experimental pKi versus predicted by model equation.
Table 1 Calculated binding energies (kcal/mol) of the first ranked Autodock Vina pose and the most relevant conformation when
different from the first Autodock Vina pose.
Ligand Exp. endpoint Pred. by model eq. Pred. mod. eq. res. Autodock Vina
Evina (rank) RMSD (A˚)
20 5.00 3.02 1.98 5.7(4) 2.62
21 5.04 2.93 2.11 6.4(8) 1.24
22 2.05 0.63 1.42 6.7(4) 1.20
28 2.92 2.88 0.04 7.8(2) 0.15
29 4.38 2.38 2.00 5.7(5) 2.64
30 4.32 2.53 1.79 6.1(6) 1.34
31 4.72 2.23 2.49 6.5(2) 3.28
32 3.00 1.49 1.51 6.0(1) 0.05
33 2.80 2.35 0.45 7.9(2) 1.24
34 3.46 3.41 0.05 7.0(2) 0.02
43 7.17 2.79 4.38 8.0(1) 0.36
66 4.78 3.07 1.71 7.5(2) 2.74
70 4.35 1.91 2.44 7.6(2) 0.49
171 2.77 2.38 0.39 7.1(2) 0.25
172 4.82 3.11 1.71 8.7(2) 0.66
4 Y. Can˜izares-Carmenate et al.2.2. Software
For the calculation of molecular descriptors, DRAGON Soft-
ware (Talete, 2007) was used. All the families of descriptors
(0D - 3D) were calculated excluding constant and near-to-Please cite this article in press as: Can˜izares-Carmenate, Y. et al., An approach to id
based on QSARINS and docking. Arabian Journal of Chemistry (2016), http://dx.dconstant variables. Program DRAGON is an application for
the calculation of the molecular descriptors, originally devel-
oped by Milano Chemometrics and QSAR Research Group,
and provides more than 1600 molecular descriptors that are
divided into 20 logical blocks.entify new antihypertensive agents using Thermolysin as model: In silico study
oi.org/10.1016/j.arabjc.2016.10.003
Figure 4 Scatter plot of experimental pKi versus predicted by LOO.
An approach to identify new antihypertensive agents 5In order to obtain the MLR model, we used the QSARINS
(QSAR-Insubria) software (Gramatica et al., 2013a,b)
developed at the University of Insubria. It would be ideal to
use all combinations of available descriptors for the calcula-
tion of the models; however, the number of combinations is
usually so great that it is impossible to calculate all models.
Therefore, to reduce the model computation time, all combina-
tions were preliminarily used with only a small number of
descriptors per model, in order to explore all combinations
of low dimension, using the all subset technique, and, later, a
genetic algorithm (GA) method was applied to develop models
based on a larger number of descriptors.
2.3. Computational techniques
2.3.1. Multiple Linear Regression
The MLR is the process that obtains a linear relationship
between the Thermolysin inhibition (pKi) and the molecular
descriptors, using ordinary least squares (OLS) algorithm
(Gramatica et al., 2013b).
For selecting the best model, the equations were ordered by
QSARINS, showing the optimum models according to R2 (the
highest value is in correspondence with the good fitting of the
model), Q2LOO (for the highest values and comparable with R
2,
the model is robust), R2Q2LOO (a lower value is indicative of
the model stability) and RMSE (should be small and as close
as possible between calculation of training, training prediction
by LOO and external prediction series).Please cite this article in press as: Can˜izares-Carmenate, Y. et al., An approach to id
based on QSARINS and docking. Arabian Journal of Chemistry (2016), http://dx.d2.3.2. Molecular docking
In this work, docking was used for the analysis of 15 com-
pounds, including two that were outside the applicability
domain of the model. Considering that the predictions of the
outlier compounds by the model can be unreliable, the docking
has allowed predicting the interactions of these compounds
with Thermolysin and other compounds with similar structural
characteristics and the best orientation of a ligand (inhibitor)
in the pocket of the aforementioned protein (Azam and
Abbasi, 2013). This computing tool has been widely used in
medical chemistry researches (Kitchen et al., 2004; Mena-
Ulecia et al., 2015; Quesada-Romero et al., 2014; Yuriev and
Ramsland, 2013).
Here, the crystallographic structure of Thermolysin was
used, and it was extracted from the Protein Data Bank, whose
code is 5DPF (Krimmer and Klebe, 2015). This protein was
refined with the addition of hydrogen and the amino acid loads
by using the graphical interface of the AutodockTool module,
which is contained in the MGLTools 1.5.6 program (Morris
et al., 2009). The same program was used to prepare the inhi-
bitors, which were saved in the pdbqt format. The Ther-
molysin inhibitors were optimized using the RHF/AM1
semi-empirical method, which is contained in the GAMMES
package (Schmidt et al., 1993), in order to obtain the most
realistic structures. In the docking experiments, a
16  16  16 box with a grid spacing of 0.375 A˚ was used.
The grid was fixed in the center of the ligands with the coordi-
nates x= 8.815 A˚, y= 40.713 A˚ and z= 5.671 A˚. Theentify new antihypertensive agents using Thermolysin as model: In silico study
oi.org/10.1016/j.arabjc.2016.10.003
Figure 5 Plot of LMO validations compared with the original model.
6 Y. Can˜izares-Carmenate et al.mode number was 10, and the maximum range of energy dif-
ferences between the computed ligands was 5 kcal/mol. Every
running of the docking was made by using the Autodock Vina
program (Trott and Olson, 2010).
2.4. Model validation according to OECD principles
Algorithm QSARINS is friendly software that can validate the
obtained model using OECD principles, in order to increase
the confidence of the predictions. According to these princi-
ples, the model should have the following: (1) a defined end-
point; (2) an unambiguous algorithm; (3) a defined domain
of applicability; (4) appropriate measures of goodness-of-fit,
robustness and predictability; and (5) a mechanistic interpreta-
tion, if possible (Worth et al., 2007).
Principle 1 is associated with the endpoint definition where
it refers to a physicochemical, biological or pharmacological
property that can be measured and, therefore, modeled. The
aim of this principle is to ensure transparency in the measure-
ment point predicted by a given model. The endpoint in this
work was the Thermolysin inhibition constant (Ki), which
characterizes substrate inhibition by a competitive inhibitor
(Kakkar et al., 1999), expressed as pKi.
According to Principle 2, QSAR models can be expressed in
the form of unambiguous algorithms, considering that the
algorithm model is the way of relating the descriptors of the
chemical structure and activity (endpoint of the model)
through mathematical models or rules based on the knowledge
developed by one or more experts. The used algorithm was aPlease cite this article in press as: Can˜izares-Carmenate, Y. et al., An approach to id
based on QSARINS and docking. Arabian Journal of Chemistry (2016), http://dx.dmathematical model of Multiple Linear Regression detailed
in the previous section.
William graph was used to define the model application
domain (DA) (Principle 3), so that reliable predictions of the
model have leverage values below the critical leverage with
± 3 standard deviations. Compounds that are outside these
ranges may be considered outliers. In addition, Insubria graph
was used for DA. This was very useful to assess the reliability
of the predictions of experimental compounds, lacking
response, and to compare with the predictions of the database.
Following the Principle 4, the goodness of the fit was eval-
uated using the coefficient of determination R2 and a modified
form R2adj that also evaluated the effectiveness by adding a new
descriptor to the model.
In order to control the robustness of the model, we carried
out internal validation strategies. First, we used the Q2LOO cri-
terion applying the technique of cross-validation (CV), i.e.,
iteratively excluding a compound from the dataset (Leaving
One Out, LOO), and then calculating a model with the remain-
ing compounds and making the prediction for the excluded
molecule. If the internal predictions were good, the value of
Q2LOO was high and comparable with R
2, so the model was
considered internally stable and robust. However, a distur-
bance of a single compound in a series of 133 cases was too
weak to show the real model robustness. Code QSARINS fur-
ther includes a stronger technique: Leaving Many Out (LMO),
which allowed studying the behavior of the model when a lar-
ger number of compounds (in this case 30% of the com-
pounds) were excluded. The model was considered stable ifentify new antihypertensive agents using Thermolysin as model: In silico study
oi.org/10.1016/j.arabjc.2016.10.003
Figure 6 Plot of Y-scrambled model compared with the original model.
An approach to identify new antihypertensive agents 7the values of R2 and Q2 calculated for each iteration of the
LMO experiment and their averages (R2LMO and Q
2
LMO)
were comparable with the values of R2 and Q2LOO of the
model.
In order to demonstrate that the model was not the result of
a chance correlation, we applied the Y-scrambling procedure.
In this procedure, responses are placed randomly, so there
was no correlation with the descriptors and, as a result, the
performance of the models should decay drastically. In this
case, if the model in the validation process was good, the val-
ues of R2 and Q2 of each iteration, and their averages (R2YS and
Q2YS) must be lesser and lesser with respect to the values of the
model.
In order to assess the model’s ability to predict new com-
pounds, an external validation was carried out. The procedure
was performed by applying the model equation obtained with
the training set, a predictive dataset, i.e., excluding compounds
that were never been used for the calculation model. Model
performance was evaluated by different criteria such as
RMSEext, Q
2-F1, Q2-F2, Q2-F3, r2M, Dr2m, CCC, and Gol-
braikh and Tropsha methods.
The mechanistic interpretation of the model (Principle 5),
although it is not mandatory, it is very desirable. In our work,
we developed a general interpretation of the model based on
the descriptors selected to describe the Thermolysin inhibition.
This could be useful to understand the different factors driving
the process.Please cite this article in press as: Can˜izares-Carmenate, Y. et al., An approach to id
based on QSARINS and docking. Arabian Journal of Chemistry (2016), http://dx.d2.5. Virtual screening
With the aim of performing identification/selection of new
compounds as Thermolysin inhibitors, the obtained model
was used for the virtual screening of the international database
Drug Bank (www.drugbank.ca), which is a database available
on the University of Alberta (Canada). These data contain
more than 1431 molecules approved by the FDA (Food and
Drug Agency of the government of the United States), 133
bioactive drugs approved by the FDA and more than 5212
experimental drugs.
3. Results and discussion
3.1. Getting QSAR-model RLM
Using the DRAGON software (Talete, 2007) we calculate 3224
descriptors (0D-3D). To perform the calculation of the 0-2D
descriptors we use molecules representation in the ChemDraw
software (saved as *.mol files). However, to carry out the cal-
culation of 3D descriptors, geometry optimization calculations
should be done; several approaches can be used (Gonza´lez and
Helguera, 2003; Goodarzi et al., 2013a,b; Perez Gonzalez
et al., 2006). In our work, we performed geometry optimiza-
tion calculations for each compound considered in this study
using the semiempirical method AM1 (Dewar et al., 1985)entify new antihypertensive agents using Thermolysin as model: In silico study
oi.org/10.1016/j.arabjc.2016.10.003
8 Y. Can˜izares-Carmenate et al.implemented in Mopac. Given the great number of variables
calculated, even when 1503 descriptors were excluded, the
number of remaining descriptors was 1721. Thus, the data
were subjected to a new filtration process using the QSARINS
software (Gramatica et al., 2013a,b) and the descriptors that
possessed more than 95% of constant values and had more
than 90% correlation were eliminated. After that, only 399
variables were considered in the selection process to develop
the model, as shown in Fig. 1.
Then, we developed several models with low multicollinear-
ity between descriptors and good correlation with the modeled
response. The generated population of models were plotted the
mean values of R2 and Q2LOO (with their standard deviations)
versus the number of variables of the model (Fig. 2), in order
to evaluate the performance of the models against their size
and to avoid overfitted models. As can be seen, the values of
R2 and Q2LOO rose as new descriptors were added to the model,
except for six and seven variables, so we can infer that the
added descriptor does not give new information. The highest
values of R2 and Q2LOO were achieved by the models of eight
variables; however, the models with five variables showed very
similar values with three less predictive variables. Based on the
principle of parsimony, we selected five variables as optimal
dimension to develop the final model, which were used to pre-
dict the Thermolysin inhibition.
The best MLR model obtained with its statistical parame-
ters is shown below:Figure 7 Williams plot. Hat diagonal
Please cite this article in press as: Can˜izares-Carmenate, Y. et al., An approach to id
based on QSARINS and docking. Arabian Journal of Chemistry (2016), http://dx.dpKi = 23.62 + 0.52xMor07u  20.77xMor12v
 3.12xR5v+ + 2.87xR5p+ + 23.58xB01[N–O]
N= 133 R2 = 0.714 R2adj = 0.702 s= 1.230
F= 63.248
R2R2adj = 0.011 LOF= 1.688 Kxx = 0.231 Delta
K= 0.100
RMSEtr = 1.202 MAEtr = 0.975 RSStr = 192.024
CCCtr = 0.833
where N is the number of compounds of the training set, R2 is
the coefficient of determination, R2adj is adjusted R
2, s is stan-
dard error of estimate, F is variance ratio, LOF is Friedman
lack of fit (Friedman, 1991a,b), Kxx is the correlation among
descriptors (Todeschini et al., 1999), Delta K is the difference
of the correlation between the descriptors (Kx) and the descrip-
tors plus the responses (Kxy), RMSEtr is Root Mean Square
Error in fitting (for training set), MAEtr is Mean Absolute
Error in fitting (calculated on training set), RSStr is Residual
Sum of Squares in fitting (also for training set) and CCCtr is
the concordance correlation coefficient calculated over the
training set (Chirico and Gramatica, 2011, 2012; Lin, 1989).
The model presented an R2 of 0.714, so it manifests a
proper fit for modeling Thermolysin inhibition. In addition,
an R2adj of 0.702, which is indicative of the convenience to
add a new descriptor to the model and, together with the
low value of the LOF parameter of 1.688, we can say that no
existing overfitting is in the model, as it presents a good fit withvalues versus standardized residuals.
entify new antihypertensive agents using Thermolysin as model: In silico study
oi.org/10.1016/j.arabjc.2016.10.003
An approach to identify new antihypertensive agents 9minimum number of descriptors. The correlation between the
model descriptors is low because the value of Kxx is small
(0.231); this allows us to assume that the model has very little
redundant information in the selected descriptors. Besides,
according to the Delta K parameter (0.1), the model has an
appropriate correlation between descriptors and the modeled
response, with a small error on the training calculations and
estimated parameters (RMSEtr = 1.202; MAEtr = 0.975;
s= 1.230). Yellow circles in Fig. 3 represent the values predicted
by the model equation versus the experimental pKi values for the
training set. This scatter plot permitted detection of systematic
trends or grouping of the data and potential outliers therein.
As can be seen, the compound NFpLA (compound 43) of
the training set has a residual of 4.38 and can be considered
an outlier compound. Keep in mind that this is the compound
that has the highest pKi in the database (pKi = 7.17), and the
pKi predicted by the model is 2.786, which leads to obtain a
very high residual value. However, the model predictions were
not affected, since a compound with predicted pKi greater than
2.5 is considered very active. The experimental pKi for Ther-
molysin and the results predicted by the MLR model for the
training set are shown in Table 1.
3.2. Model validation according OECD principles
In order to validate our model, we followed the OECD regula-
tory principles to ensure their validity, checking the model per-
formance, i.e., the fitting, stability in the cross-validation andFigure 8 Insubria graph. Hat diago
Please cite this article in press as: Can˜izares-Carmenate, Y. et al., An approach to id
based on QSARINS and docking. Arabian Journal of Chemistry (2016), http://dx.dthe ability to predict new compounds (Worth et al., 2007).
The fitting and stability of the model were evaluated using
internal validation procedures; first, we take into account the
parameters of the cross-validation Leave-One-Out (LOO).
According to the obtained results, it is possible to affirm that
the internal predictions are good since the variance explained
in the prediction by LOO (Q2Loo = 0.6868) has a comparable
value with R2 = 0.7135. Then, the model is considered inter-
nally stable or robust with a small error in the predictions
(RMSEcv = 1.2563 and MAEcv = 1.0190). Fig. 4 shows the
values predicted by LOO versus the experimental values of
pKi (clear circles for the training set and dark circles for the
prediction set). As in the model predictions, the NFpLA com-
pound is the farthest from the line and is supported by
the hypothesis of which it can be considered an outlier
compound.
A stronger technique included in the QSARINS is Leaving-
Many-Out (LMO), which was developed leaving out the 30%
of the dataset to study the behavior of our model. This tech-
nique was very useful in our database because in opposite to
LOO, where for each single disturbance of the data the influ-
ence on the predictions was very weak; in LMO technique,
each perturbation of data is significant. The model is consid-
ered stable because the R2 = 0.7135 and Q2LMO = 0.6810 val-
ues are comparable, and calculation in each iteration of LMO
and their averages are comparable to the values of R2 and
Q2LOO of the model. Fig. 5 shows the Q
2
LMO versus the correla-
tion between descriptors and Thermolysin inhibition (Kxy) innal values versus predicted data.
entify new antihypertensive agents using Thermolysin as model: In silico study
oi.org/10.1016/j.arabjc.2016.10.003
Figure 9 Conformational comparison of compounds 20, 21 and 22 (in yellow) from the crystal structures in Thermolysin–5H9a inhibitor
complex (inhibitor in red). a: N-[(S)-({[(benzyloxy)carbonyl]amino}methyl)(hydroxy)phosphoryl]-L-leucyl-4-methyl-L-leucine-(6S,9S)-1-
(benzyloxy)-6-isobutyl-9-neopentyl-4-oxido-1,4,7-trioxo-2,5,8-triaza-4-phosphadecan-10-oate (C22 H36 N3 O7 P).
Figure 10 Representation of the interactions of the compound 43 (A) and 172 (B) in the active center of the Thermolysin. The
interaction surface with the solvent has been shaded. The polar area of interaction has been represented with blue ribbons; the
hydrophobic area, with green ones, and the density of negative charge, with red ones. The interaction with the Zn2+ has been represented
with a gray line.
10 Y. Can˜izares-Carmenate et al.which it is observed that the values of Q2LMO are very similar to
each other, which confirms that the model has a good fit,
robustness and stability.Please cite this article in press as: Can˜izares-Carmenate, Y. et al., An approach to id
based on QSARINS and docking. Arabian Journal of Chemistry (2016), http://dx.dIn order to demonstrate that the model was not the result of
a casual correlation, the Y-scrambling procedure was used,
placing the answers at random, so that there was no correla-entify new antihypertensive agents using Thermolysin as model: In silico study
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An approach to identify new antihypertensive agents 11tion with descriptors and, as a consequence, the model
performance decayed dramatically. The values of R2 and Q2
of each iteration and its averages (R2Y-scr and Q
2
Y-scr) give us
the criteria that the model is good, since these parameters
are ever lower with respect to the values of the model
(R2Y-scr = 0.039 and Q
2
Y-scr = 0.055). The R2Y-scr and Q2Y-scr
values against R2 and Q2 of the model are shown in Fig. 6.
Notice that the values of R2 and Q2 of the model are very
far from the values obtained for those parameters in the
Y-scrambling experiment, which indicates that the model was
not obtained as a result of a random correlation.
The predictive ability of the model was tested using a series
of external predictions, which were never used to obtain the
model (external validation). Using this procedure, we checked
the ability of the model to predict new compounds and their
parameters showing results equivalent to the value of model
R2 (R2ext = 0.723), RMSEext = 1.182, MAEext = 0.91,
PRESSext = 60.091, Q
2-F1 = 0.713, Q2-F2 = 0.713, Q2-
F3 = 0.723, CCCext = 0.817, r
2
m_aver = 0.619,
r2m_delta = 0.126.
Where R2ext is the external determination coefficient
(Golbraikh and Tropsha, 2002), RMSEext is the Root Mean
Square Error in external prediction; MAEext is the Mean
Absolute Error in external prediction; PRESSext is the Predic-
tive Residual Sum of Squares (external validation); Q2-F1 (ShiFigure 11 Structurally similar compounds
Please cite this article in press as: Can˜izares-Carmenate, Y. et al., An approach to id
based on QSARINS and docking. Arabian Journal of Chemistry (2016), http://dx.det al., 2001), Q2-F2 (Schu¨u¨rmann et al., 2008), and Q2-F3
(Consonni et al., 2009) are the variances explained in external
prediction; CCCext is the Concordance Correlation Coefficient
(Chirico and Gramatica, 2011, 2012; Lin, 1989) and r2m_aver
and r2m_delta are the Roy criteria: average and delta (Ojha
et al., 2011). The predictions of compounds in the external
set can be seen in Fig. 3 (blue circles).
A crucial problem in chemometrics and QSAR studies is
the definition of the applicability domain (AD) of a classifica-
tion or regression model. Even with a robust, significant and
validated QSAR model, unreliable predictions of the modeled
property for the entire universe of chemical compounds can be
expected. Indeed, only predictions for compounds that fall
within the AD can be considered reliable and not the extrapo-
lation of the models (Dimitrov et al., 2005).
In this study, we used the approach of leverage (h) and stan-
dardized residuals described in the technical literature
(Atkinson, 1985). Fig. 7 shows the William graph of the model,
where open circles represent the compounds of the training
and dark circles represent the prediction set.
As shown in this figure, most of the compounds are within
the applicability domain of the model. There is only one com-
pound (compound 34) with the value greater than the critical
leverage (h= 0.192), but showing residual within the limits,
and one compound (compound 43), having residual off-to compound 43 proved with docking.
entify new antihypertensive agents using Thermolysin as model: In silico study
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Figure 12 Structurally similar compounds to compound 34 proved with docking.
Figure 13 Representation of the interactions of the compound 34 (A) and compound 32 (B) in the active center of the Thermolysin. The
interaction with the solvent has been shaded. The polar area of interaction has been represented with blue ribbons; the hydrophobic area,
with green ones, and the area with density of negative charge, with red ones.
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An approach to identify new antihypertensive agents 13limits (3.62) though this is within critical leverage. Both cases
must be taken into account as potential outlier compounds.
Besides, the QSARINS provided a new approach for deter-
mining the model applicability domain based on leverage and
model predictions. The Insubria graphic is very useful to eval-
uate the position of the molecules lacking experimental
response, compared with the structural applicability domain,
and to compare their predictions with the compounds having
the experimental values. According to the graph of Insubria
(Fig. 8), only one compound is outside the AD by leverage
(compound 34) and coincides with the William graph.
As shown in the model equation, using only five predictors
(molecular descriptors), more than 70% of the inhibitory activ-
ity of Thermolysin can be described. Most of the variables are
three-dimensional (Mor07u, Mor12v, R5v+ and R5p+) of
3D MoRSE and GETAWAY families, respectively. This result
is logical, since there are reports that the enzyme is stereospeci-
fic (Jin and Kim, 1997), so the three-dimensional structure of
the inhibitors is essential for access and interaction with the
active site and subsite pockets of the enzyme. Note that
descriptors weighted by the van der Waals volume have a neg-
ative coefficient that could be related to the steric hindrance to
access the active site inside. In addition, the descriptor
weighted by polarizability has a positive coefficient, which
reinforces the idea that electrostatic interactions with residues
near the active site of the enzyme are crucial to their catalytic
activity. Furthermore, the model has a two-dimensional (2D)
descriptor (B01 [NO]), based on the search for similar patterns
in the database compounds. These suggest that the presence of
very close nitrogen atoms and oxygen atoms permits the inter-
action with the active site of the enzyme.
3.3. Molecular docking
First, the method of the docking to reproduce the crystal struc-
ture of the Thermolysin-inhibitor complex (Fig. 9) was made.Figure 14 Scheme of
Please cite this article in press as: Can˜izares-Carmenate, Y. et al., An approach to id
based on QSARINS and docking. Arabian Journal of Chemistry (2016), http://dx.dThis test allowed measuring the capacity of the docking to
reproduce known structures, which were contained in a crystal.
As it is shown in Fig. 9, the docked structures had an ade-
quate orientation in the pocket of Thermolysin. It reproduces
in an acceptable way the X-ray crystal structure of the
Thermolysin-inhibitor complex. The root mean square devia-
tion (RMSD) of the analyzed molecules regarding the crystal
structure of the inhibitor was <2.0 A˚ in the 73.3% of all the
analyzed cases (Table 1). In this analysis, it was considered
that 2.0 A˚ is the reference value that identifies an either correct
or incorrect resolution of the docking (Gohlke et al., 2000).
The RMSD has often been used to measure the quality of
reproduction of a known (i.e. crystallographic) binding pose
by a docking method (Gohlke et al., 2000). Several authors
have suggested that a low RMSD with respect to the true bind-
ing pose (in our case the crystallographic structure of
Thermolysin-inhibitor (5H9) complex), is good (ideally less
than 1.5 A˚, or even better, less than 1 A˚). This represents good
reproduction of the correct pose. Beware reading much signif-
icance into relative values of RMSD’s greater than 3 A˚. A
binding pose with RMSD 4 A˚ is not better than one of 6 A˚.
They are both equally poor (i.e. wrong) (Gohlke et al., 2000;
Liebeschuetz et al., 2012; Maiorov and Crippen, 1994). Only
the compounds 20, 29, 31 and 66 had values higher than 2.0 A˚.
Analyzing the docking results, it is worth mentioning that
the compound 172 presented the lower union energy
(8.7 kcal/mol) of all the analyzed molecules. As Fig. 10B
shows, the orientation of one of the OH groups makes that
it coordinates with the metal (Zn2+) in the active center of
the protein. Besides, one of the terminal benzenes is located
in a hydrophobic pocket, formed by Leu133, Val139, Phe130
and Leu202, whereas the other benzene terminal is located in
a hydrophobic area that has been formed by the amino acids
Trp115 and Tyr157, which stabilize the molecule. The terminal
OH groups are oriented toward a polar area that has been
formed by the Asn227. The Asp226 is also located in this area.virtual screening.
entify new antihypertensive agents using Thermolysin as model: In silico study
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14 Y. Can˜izares-Carmenate et al.It is anionic and it provides density of charge in the stabiliza-
tion of these groups.
Of all analyzed compounds, two of them were identified as
possible outliers (Compounds 34 and 43) from QSAR method
results. In this sense, we made experiments of molecular dock-
ing of these ‘outlier’ compounds and a group of compounds
with similar structural characteristics, since the model pro-
vided three-dimensional information of molecules, and it
would be interesting to observe their behavior in the active site
of Thermolysin. In order to analyze the actions of compound
43 in the active site of the enzyme, besides, seven compounds
were considered by the similarity therewith; they are shown
in Fig. 11.
Of all compounds in the dataset, the compound 43 is the
most active (pKi = 7.17); in other words, this compound is
an excellent inhibitor of Thermolysin. This molecule behavedTable 2 Compounds predicted by the model in Group 3 (pKi > 3.
DRUGBANK-
ID
Pred. by model eq. HAT i/i
(h* = 0.1353)
LAI D
I
DB01462 3.518 0.044 0 D
DB01523 4.138 0.048 0 D
DB00239 4.043 0.084 0 D
DB00606 3.935 0.059 0 D
DB00734 4.135 0.057 0 D
DB00850 3.821 0.056 0 D
DB00909 3.576 0.112 0 D
DB00932 5.581 0.067 0 D
DB00933 4.056 0.091 0 D
DB00941 3.613 0.085 0 D
DB00944 4.570 0.101 0 D
DB01076 3.663 0.086 0 D
DB01147 3.503 0.047 0 D
DB01267 3.947 0.051 0 D
DB01289 5.062 0.059 0 D
DB01406 4.343 0.096 0 D
DB01601 4.937 0.117 0 D
DB04845 3.662 0.129 0 D
DB01630 5.556 0.127 0 D
DB01987 3.781 0.081 0 D
DB02038 4.146 0.079 0 D
DB02090 4.492 0.112 0 D
DB02093 3.595 0.086 0 D
DB02225 3.506 0.111 0 D
DB02243 4.444 0.086 0 D
DB02269 3.593 0.088 0 D
DB02276 5.763 0.112 0 D
DB02449 3.839 0.043 0 D
DB02598 4.284 0.126 0 D
DB02613 3.699 0.126 0 D
DB02673 3.920 0.075 0 D
DB02723 5.528 0.077 0 D
DB02783 3.732 0.089 0 D
DB02814 4.002 0.078 0 D
DB02851 3.680 0.123 0
HAT i/i: leverage value taken from the hat matrix diagonal. HAT value
model variables plus one and n is the number of the objects used to calcu
et al., 2013b).
LAI: Lipinski Alert Index or ‘the rule of 5’ is a filter that identifies com
absorption or permeation. The alert index is a dummy variable taking va
1997, 2001).
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of union (8.0 kcal/mol), compared with other evaluated com-
pounds (see Table 1) that have similar structural characteris-
tics. This molecule is oriented in the active center of
Thermolysin, in such a way that the terminal benzenes are
located in a hydrophobic pocket, formed by the amino acids
Phe130, Leu202, on the one hand, and Phe114, Trp115,
Tyr157 and the Ala113, on the other, which gives stability to
the complex. Moreover, the Asp213, when being anionic, sta-
bilizes that area and attracts both terminal OHs, which present
hydrogens with a lack of charge, stabilizing even more the
complex (Fig. 10A).
According to these results, it is confirmed that this com-
pound is very active. However, the pKi predicted by our model
is similar to those values of structurally related compounds,
instead of their real value, so the residual is large. This suggests5).
RUGBANK-
D
Pred. by model eq. HAT i/i
(h* = 0.1353)
LAI
B02888 4.333 0.101 0
B03010 4.574 0.091 0
B03076 3.807 0.071 0
B03104 3.506 0.092 0
B03141 4.784 0.107 0
B03507 6.631 0.134 0
B03549 4.516 0.055 0
B03579 4.146 0.079 0
B03591 4.424 0.086 0
B03712 3.857 0.097 0
B03768 4.327 0.064 0
B03787 4.146 0.079 0
B03880 4.647 0.058 0
B04150 4.258 0.069 0
B04287 3.874 0.098 0
B04310 3.863 0.090 0
B04363 3.669 0.083 0
B04495 5.219 0.102 0
B04502 6.728 0.124 0
B04609 4.473 0.060 0
B04659 5.230 0.079 0
B04709 4.235 0.082 0
B04722 3.8103 0.046 0
B04772 3.9996 0.052 0
B04779 4.0673 0.061 0
B00886 4.2398 0.054 0
B05025 3.5649 0.057 0
B05100 5.7736 0.131 0
B05316 3.6097 0.077 0
B05790 5.7223 0.135 0
B05796 4.7386 0.104 0
B05804 3.9205 0.101 0
B06258 3.5556 0.076 0
B06515 3.9857 0.089 0
s higher than the cutoff value h* = 3p0/n, where p0 is the number of
late the model, are considered X-outliers (Atkinson, 1985; Gramatica
pounds with low probability of useful oral activity because of poor
lue 1 when two or more properties are out of range (Lipinski et al.,
entify new antihypertensive agents using Thermolysin as model: In silico study
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An approach to identify new antihypertensive agents 15that the high experimental activity of compound 43 could be a
consequence of the difficulty in hydrolyzing the molecule. Note
that compounds with lower Evina (66, 70 and 172) have a
hydrolyzable bond near to the phosphorus atom in the chain
(P–O– or P–NH–). This enables that the molecule stay longer
time in the active site of Thermolysin and, thus, their large
value of activity with respect to other structurally similar mole-
cules; for this reason, we decided to keep this compound in the
training set.
In the case of compound 34, it has a very close-to-zero
(0.05) residual, so the prediction of this compound by the
model is very good. However, this compound is outside the
critical leverage, indicating that it may be a structural outlier.
As shown in Fig. 12, we can see that it exists in the database
other thiols nearby from the structural point of view (com-
pounds 28–33); nevertheless, this compound has the lowest
RMSD of all tested molecules (see Table 1) and low energy
of union (7.0 kcal/mol).
The low energy of union above is due to its stabilization in
the active center of the Thermolysin in a polar area, formed by
the histidines 142 and 231, besides the Asn112. This area sta-
bilizes the OH terminal groups (Fig. 13A). Besides, the termi-
nal benzene is stabilized in a hydrophobic area that is formed
by Trp115 and Tyr153. Note that the interactions of the com-
pound 34 (Fig. 13A) and compound 32 (Fig. 13B), in the active
center of Thermolysin, involve the same residues (His 142, 146
and 231; Glu 143 and 166; Ala113; Phe114; Trp115 and
Tyr157). From the foregoing, we decided to maintain also
the compound 34 in the training set of the model.
3.4. Virtual screening
In this report, the main objective was to identify new com-
pounds with inhibitory activity of Thermolysin, considering
that they were predicted by the model as active, were within
the AD and possessed suitable pharmacokinetic characteristics
for oral administration. For the division into virtual screening,
it was considered different pKi values, which were separated
into three groups according to their activity, reported by
Klopman and Bendale (1989): inactive (pK< 0522), margin-
ally active (0.522 6 pKi < 0022) and active (pKi
P 0.022). According to that, we decide to carry out a new
division for the active compounds: Group 1
(0.022 6 pKi < 2.5), Group 2 (2.5 6 pKi < 3.5) and Group
3 (pKiP 3.5). Fig. 14 shows the filtering process carried out
in the database Drug Bank. As a result, 141 compounds were
predicted by the model as belonging to Group 2 (Table S-2 of
supplementary material) and 69 were predicted in Group 3;
these compounds and their predicted values can be seen in
Table 2.
4. Conclusions
In the present study, a QSAR-RLMmodel was developed using molec-
ular descriptors of Dragon software, which adequately predicted the
inhibitory activity of the enzyme Thermolysin.
This model fulfilled all regulatory principles established by the
OECD; the robustness of the model was tested through exercised inter-
nal validation (LOO, LMO and Y-scrambling), and its predictability
was determined with an external prediction set (external validation).
Two possible outliers were identified in the model application domain
but, in a molecular docking study, they showed good activity, so wePlease cite this article in press as: Can˜izares-Carmenate, Y. et al., An approach to id
based on QSARINS and docking. Arabian Journal of Chemistry (2016), http://dx.ddecided to keep both in our database. Finally, a virtual screening
experiment was performed for the Drug Bank database. The model
identified 141 compounds as potential Thermolysin inhibitors with
pKi value between 2.5 and 3.5, as well as 69 compounds with pKi value
greater than 3.5; future evaluation of these compounds could be a step
forward in the search of new Thermolysin inhibitors.
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